Tempus AI Share Price: TEM Quote & Analyst Forecast

Current Price: $57.32 ·
Market Cap: 10.19B ·
52-Week Range: $39.01 – $104.32 ·
P/E Ratio: -40.35 ·
Analyst Consensus: Moderate Buy

The data below aggregates key metrics from leading financial platforms to give a complete picture of where TEM stands today.

Is Tempus AI a good stock to buy now?

The question hangs over every investor considering TEM: does the bullish revenue story justify buying here, or has the stock run too far already? The answer depends on which analyst you ask.

Analyst Ratings

Fourteen Wall Street analysts track Tempus AI, and their collective verdict lands at “Moderate Buy”—a rating that reflects neither enthusiasm nor dismissal, but a studied middle ground. The breakdown shows 7 analysts recommending buy, 8 holding steady, and just 1 pushing sell. TipRanks data shows 23 buy ratings against 107 holds and 11 sells over the recent month, though this counts all tracked analysts rather than the current consensus.

HC Wainwright recently raised its target from $89 to $95, maintaining a Strong Buy stance—among the most bullish on the street. Needham, meanwhile, reiterated its Strong Buy with a $75 target on March 11, 2026. Both firms point to Tempus’s data moat and expanding contracts as justification for elevated expectations.

JP Morgan took the opposite path in late February, lowering its target from $80 to $60 and maintaining a Hold rating. The firm cited the stock’s valuation following a 160% year-to-date gain as of late 2025. Morgan Stanley followed suit in early March, cutting its price target from $85 to $70 while keeping a Buy rating—acknowledging growth potential but questioning near-term upside at current levels.

Pros and Cons

Tempus AI’s investment case rests on a straightforward trade-off. On the positive side: genomics revenue surged 117.2% to $252.9 million, quarterly revenue of $334.2 million crushed expectations, and the company sits on a $1.1 billion backlog that could fuel future quarters. The Quick Ratio of 2.89 suggests solid short-term liquidity, and the company anticipates growth from new pharma contracts and MRD testing reimbursement.

On the negative side: gross margins contracted from 76.8% in the prior quarter to 69.7%, operating losses persist, operating cash flow declined, and debt remains on the balance sheet. The EV/S multiple expanded from 7x to 11x despite limited fundamental change, suggesting the market has already priced in substantial future performance.

What is the price target for Tempus?

Price targets for TEM span a remarkably wide range, from $52 on the low end to $110 on the high—a gap that reflects divergent views on growth sustainability versus valuation reasonableness.

Current Forecasts

MarketBeat, tracking 16 analysts, shows an average 12-month price target of $79.38, which represented an 11.03% downside from the $89.23 closing price recorded on October 24, 2025. The high target of $110 and low of $52 bracket a substantial range that investors must navigate.

Zacks, drawing on 10 analysts, places the average short-term target at $66.70, implying 14.98% upside from a $58.01 closing price. StockAnalysis reports 12 analysts consensus at $72.83 with 28.27% upside, while a separate window shows 11 analysts averaging $79.45 with 86.41% upside from a different baseline price.

TipRanks data shows a consensus of $84.40 from 11 analysts, with targets ranging from $60 to $110. Investing.com aggregates 15 analysts with an average target of $72.40 and high of $100. The sector comparison reveals TEM’s consensus rating score of 2.38 sits marginally above the medical sector average of 2.33, suggesting slightly more bullish positioning than peers.

Long-term Predictions

Simply Wall St projects annual revenue growth of 17.6%, earnings growth of 48% per annum, and EPS growth of 45.9%—figures that imply a company maturing from hypergrowth into sustainable expansion. The firm’s three-year forecast calls for Return on Equity of 31.5%, a strong return that reflects improving profitability metrics.

TIKR offers a more aggressive model, targeting $112.30 with 109.1% upside potential, though this tier-3 source carries lower confidence. The same firm reports a consensus target of $86.71 from its aggregated model, implying 61.4% upside from a $53.71 reference price.

Is Tempus AI making money?

Revenue growth tells only half the story. The other half involves the profit question—and for Tempus AI, that question remains answered with a qualified “not yet.”

Revenue Growth

The top-line picture impresses. Total revenue grew 84.7% year-over-year, with genomics revenue specifically climbing 117.2% to $252.9 million. Quarterly revenue of $334.2 million exceeded analyst expectations, and TIKR reports a revenue CAGR of 83.4% over the past year. These figures place Tempus among the fastest-growing players in healthcare AI and genomics.

The growth engine appears sustainable: new pharma contracts are expected to drive top-line expansion, and MRD (minimal residual disease) testing reimbursement could unlock a recurring revenue stream that transforms the business model from project-based to subscription-adjacent.

Profitability Status

But the bottom line tells a different story. The P/E ratio of -40.35 confirms Tempus remains unprofitable by conventional measures. Gross margins declined from 76.8% in the prior quarter to 69.7%—a 7.1 percentage point contraction that raises questions about pricing power and cost structure as the company scales.

Operating cash flow declined in the most recent period, and analysts flag operating losses alongside debt presence on the balance sheet. The EV/S multiple expansion from 7x to 11x despite limited fundamental change suggests the market is valuing future profitability rather than current earnings.

The pattern: Tempus shows exceptional top-line momentum but has yet to prove it can convert that growth into sustainable profits—a distinction that separates the bulls from the bears.

Does Tempus AI have a future?

The future question hinges on whether Tempus can translate its data assets into sustainable profits. Analysts see a path, but the road includes notable obstacles.

Growth Projections

Simply Wall St’s growth model projects revenue increasing 17.6% annually, earnings climbing 48% per annum, and EPS growing 45.9%. These projections imply a company entering a more mature phase where scale begins to improve margins. The three-year Return on Equity forecast of 31.5% suggests management could deliver shareholder returns once profitability establishes itself.

The $1.1 billion backlog provides a pipeline buffer: contracts already signed but not yet recognized as revenue offer visibility into future quarters. New pharma partnerships and expanding MRD testing reimbursement access could convert this backlog into top-line growth.

Market Position

Tempus occupies a distinctive position in healthcare AI, leveraging its data moat to support clinical decisions. The company faces risks from competition, regulatory challenges, and operating losses—but these risks are common to the sector rather than unique to Tempus.

The market has priced substantial optimism: despite limited fundamental change, the EV/S multiple expanded from 7x to 11x. This valuation leaves little room for execution misses.

The catch: the EV/S multiple of 11x prices in flawless execution across all three growth levers—data moat expansion, contract conversion, and reimbursement expansion.

Who is Tempus AI’s biggest competitor?

Pinpointing Tempus AI’s single biggest competitor proves difficult in the fragmented healthcare AI space, where companies compete on different dimensions—data access, algorithm sophistication, clinical integration, and regulatory positioning.

Top Competitors

Tempus operates in a competitive landscape alongside other precision medicine platforms. The key differentiator remains data depth: Tempus’s accumulated clinical and genomic datasets represent a moat that takes years to replicate. Competitors include established healthcare AI players, genomics testing companies, and hospital system data platforms.

MarketBeat’s competitor analysis positions TEM alongside medical technology and diagnostic companies. The competitive threat intensifies as AI capabilities democratize and more players enter the data-driven healthcare space.

MarketBeat Analysis

MarketBeat’s sector comparison reveals TEM’s consensus rating score of 2.38 sits marginally above the medical sector average of 2.33. This marginal outperformance suggests Tempus trades roughly in line with peers rather than commanding a clear leadership premium—despite its distinctive growth profile.

The pattern: TEM holds a growth premium over peers but does not translate that into a consensus leadership rating, suggesting investors and analysts see the competitive landscape as still very much in play.

What do analysts say about TEM?

Professional opinions span a wide spectrum, reflecting genuine disagreement about Tempus AI’s risk-reward profile.

“The consensus among Wall Street analysts is that investors should ‘hold’ TEM shares.”

— MarketBeat analyst aggregator tracking 16 firms

“We are downgrading TEM to Hold as we see the stock more fairly valued following the strong performance [38% since September 30 and 160% year-to-date].”

— Unnamed analyst via TipRanks

“Tempus AI offers a massive 109.1% projected total return potential.”

— TIKR valuation model provider

“A dominant data moat successfully weaponizing artificial intelligence to redefine clinical care.”

— TIKR valuation model provider

The pattern emerges clearly: bulls point to the data moat and backlog visibility; bears flag valuation and margin pressure. Both sides have defensible positions.

Tempus AI Stock: The Stakes

Tempus AI sits at an inflection point. The company has demonstrated it can grow revenue at exceptional rates—the 84.7% year-over-year expansion and 117.2% genomics growth prove the market opportunity is real. But growth and profitability are different animals, and Tempus has yet to prove it can deliver the latter.

Gross margin compression from 76.8% to 69.7% in a single quarter raises operational questions. The presence of debt and declining operating cash flow suggest the burn isn’t over. Yet the backlog visibility, new pharma contracts, and MRD reimbursement expansion point toward a path forward—if execution follows.

The divergence among analysts—from HC Wainwright’s $95 target to JP Morgan’s $60—captures this uncertainty. The stock is neither obviously cheap nor clearly expensive; it’s priced for a future that depends on Tempus converting its data advantage into durable profits.

For growth-oriented investors with high risk tolerance, the $57 range may represent an attractive entry before the story clarifies. For conservative investors prioritizing profitability metrics, waiting for margin stabilization before establishing a position makes more sense. The choice reflects not just financial analysis but honest self-assessment of investment goals.

Related reading: BHP share price LSE

Tempus AI’s impressive 84.7% revenue growth continues to drive investor interest, where live Tempus AI share price data reveals real-time fluctuations alongside analyst targets.

Frequently asked questions